Brenig Therapeutics

DOVER, DE, USA I November 26, 2024 I Brenig Therapeutics announced the initiation of the first-in-human clinical trial for BT-267, a best-in-class LRRK2 inhibitor developed as a potential disease-modifying treatment for idiopathic and LRRK2-associated Parkinson’s disease. Advancement of Brenig’s clinical program is supported by a recent $65 million financing round, led by New Enterprise Associates. The trial began in November 2024, dosing healthy volunteers to evaluate BT-267’s safety and tolerability. Following this initial assessment, proof-of-concept studies are planned for patients with idiopathic Parkinson’s disease. Preclinical data underscores the potential of BT-267 as the best-in-class LRRK2 inhibitor, confirming a superior safety profile, with little or no visible lung or kidney morphological changes at the highest tested doses in GLP toxicology studies and exceptional pharmacokinetics, including high cerebrospinal fluid (CSF) to plasma unbound ratio. BT-267 benefits from cutting-edge computer-aided drug design, AI/ML computational pharmacology, biomarker models, and the structural biology expertise of its partner Expert Systems Accelerator. Brenig’s advanced approach to predictive biomarkers may help position BT-267 candidate as a promising disease-modifying therapy for Parkinson’s, including idiopathic cases that lack known genetic drivers. About Brenig Therapeutics Brenig Therapeutics is a biotechnology company committed to pioneering innovative therapies for neurodegenerative diseases. Through advanced science and a focus on patient needs, Brenig aims to deliver transformative solutions to address the root causes of these debilitating conditions. SOURCE: Brenig Therapeutics

In another major milestone in the field of innovative healthcare, on July 23, 2024, Boston-based biotech company Brenig Therapeutics announced that it has successfully closed A $65 million Series A funding round. The round was led by New Enterprise Associates (NEA), a well-known venture capital firm, The participation of several heavyweight investors, including OrbiMed, Torrey Pines Investments and BioGeneration Ventures, shows the broad recognition and expectation of Brenig Therapeutics. Brenig Therapeutics is a pioneering company focused on the treatment of neurological diseases, particularly in the use of artificial intelligence and machine learning technology to develop new drugs. The focus of its development is on BT-267, an innovative small molecule inhibitor that targets the LRRK2 protein. Mutations in the LRRK2 gene are one of the major genetic factors that cause Parkinson's disease, so the development of BT-267 is of great significance for the treatment of Parkinson's disease. Iain Dukes, Chairman of Brenig Therapeutics, said: "This financing not only provides us with the financial support to achieve our goal, but more importantly, it gives us the opportunity to address the urgent medical needs of patients with Parkinson's disease through differentiated medicines." This move by OrbiMed partner Iain Dukes is seen as a strong endorsement of Brenig Therapeutics' advanced technology and its dedicated team. The funding will be used to advance preclinical studies of BT-267 while supporting another undisclosed clinical program at Brenig Therapeutics. According to sources, Brenig plans to move BT-267 into clinical trials in 2025. Given the importance of LRRK2 inhibitors in the treatment of Parkinson's disease, the industry generally believes that Brenig's technical advantages have the potential to bring revolutionary breakthroughs in this field. In the global battle against Parkinson's disease, this advance by Brenig Therapeutics offers new hope for patients. With the deep integration of technology and medicine, it is reasonable to expect more innovative therapies to be developed to address this global public health challenge.

Today, a brief rundown of news from Dren Bio and Geron as well as updates from Moderna, Brenig Therapeutics and Agilent that you may have missed.Novartis is investing in bispecific antibodies for cancer, agreeing to pay privately held Dren Bio $150 million to collaborate on experimental drugs designed to trigger a tumor-destroying responseby myeloid cells. The upfront payment includes a $25 million equity investment in Dren Bio, and the biotechnology company could receive up to $2.85 billion in additional payments based on achievement of certain milestones. Dren Bio and Novartis will collaborate on development until specific experimental drugs have been identified, after which Novartis will assume full responsibility for development, approval and commercialization. Jonathan GardnerAnil Kapur, the chief commercial officer for Geron, is leaving the biotech at the end of next month to pursue other interests, Geron said Tuesday. The departure of Kapur, who was appointed commercial head in late 2019, is notable as Geron just won U.S. approval of its first drug, Rytelo for myelodysplastic syndromes. Gerons COO, Andrew Grethlein, will serve in Kapurs role on an interim basis as the company searches for a replacement. Ned PagliaruloProlific researcher and biotechnology entrepreneur Robert Langer is stepping down from the board of directors of Moderna, a company he helped found in 2010. His resignation did not result from any disagreement with the company, Moderna said in a regulatory filing. Another Moderna director, Stephen Berenson, has also stepped down and will be replaced by David Rubenstein, the co-founder and co-chairman of investment firm The Carlyle Group. Moderna is searching for Langers successor. Ned PagliaruloBrenig Therapeutics on Tuesday announced the closing of a $65 million Series A fundraising round. Formed three years ago, the startup plans to use the fresh cash to push its most advanced drug into human testing. The drug is supposed to inhibit LRRK2 a gene that, when mutated, becomes one of the most common drivers of Parkinsons disease. Venture capital firm New Enterprise Associates led the round, which also saw participation from healthcare investors like OrbiMed and BioGeneration Ventures. Jacob BellBiovectra, a Canada-based contract development and manufacturing organization, has agreed to sell to Agilent Technologies for $925 million. Biovectra makes the active ingredients in pharmaceuticals and assists in other elements of production like fill-finish services, lipid nanoparticle formulation and large-scale commercial manufacturing. Agilent, which offers laboratory services to drugmakers, said the deal will help build its CDMO business and bring in expertise in fast-growing segments such as antibody drug conjugates and GLP-1 medicines. Jacob Bell '